Copyright © Queen's Printer,

Victoria, British Columbia, Canada

Licence

Disclaimer

Volume 55, No. 13

192/2012

The British Columbia Gazette,

Part II

July 3, 2012

B.C. Reg. 192/2012 , deposited June 26, 2012, pursuant to the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [section 22 (1)]. Resolution of the Board of the College of Pharmacists of British Columbia, dated April 12, 2012.

Resolved that, in accordance with the authority established in

section 22 (1) of the Pharmacy Operations and Drug Scheduling Act , and subject to filing with the Minister as required by

section 22 (2) of the P harmacy Operations and Drug Scheduling Act , the board amend the Drug Schedules Regulation, B.C. Reg. 9/98, as set out in the

schedule attached to this resolution.

— B. NAKAGAWA, BSc (Pharm), FCSHP, Registrar .

Schedule

1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in the Schedules

(

a) by striking out the following:

1 Apiol, oil of (parsley oil)

1 Centella asiatica extract and active principles thereof v

1 Deanol and its salts and derivatives

1 Dimethyl sulfoxide

1 Dopamine and its salts

1 Gold and its salts

1 Ibuprofen and its salts (when sold in strengths greater than 400 mg per solid dosage form or per 5 mL liquid dosage form)

1 Levocarnitine and its salts and derivatives

1 L-Tryptophan, when sold as a single ingredient

1 Theobromine and its salts

1 Uracil and its salts , and

(

b) by adding the following:

1 Dimethyl sulfoxide, for veterinary use or when sold for the treatment of interstitial cystitis or scleroderma in humans

1 Dopamine and its salts, when sold for administration by injection

1 Dutasteride

1 Gold and its salts and derivatives, when sold for administration by injection

1 Ibuprofen and its salts except when sold for oral administration in a concentration of 400 mg or less per dosage unit

3 Ibuprofen and its salts containing 400 mg or less per oral dosage unit (when sold in package sizes exceeding 18 000 mg)

1 Levocarnitine and its salts and derivatives, when sold for the treatment of primary or secondary levocarnitine deficiency

1 L-Tryptophan, when sold

(

a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other ingredients, or

(

b) for human or veterinary use as a single ingredient intended for any route of administration other than oral

1 Uracil and its salts, when sold for the treatment of cancer .

Copyright © 2012: Queen's Printer, Victoria, British Columbia, Canada